Skip to main content
SpringerLink
Log in

Efficacy of Supplemental Anti-Inflammatory Therapy with Fenspiride in Chronic Obstructive and Nonobstructive Bronchitis

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: The objective of this randomised, nonblind study was to assess the efficacy of fenspiride as complementary anti-inflammatory therapy in combination with ipratropium bromide in patients with chronic bronchitis (CB). A comparison was made with ipratropium bromide alone, the generally accepted standard therapy for CB.

Methods and subjects: The study population comprised 20 patients with chronic obstructive bronchitis (COB) and 60 patients without signs of obstruction. Fifty-one males (64%) and 29 females (36%) aged from 25 to 65 years were studied over a 6-month treatment period. Combined therapy with fenspiride (160 mg/day) and ipratropium bromide (160 μg/day) was prescribed to 39 patients (28 with CB and 11 with COB) for 6 months, and monotherapy with ipratropium bromide (160 μg/day) was prescribed for 41 patients (32 with CB and nine with COB).

Results: The combined therapy group had a reduced intensity of dyspnoea, improvements in sputum nature and quantity of exudation, and a reduced intensity of coughing. The monotherapy group showed reductions in sputum exudation and cough intensity. Improvements in lung respiratory function were observed in both groups, but were greater in the combined therapy group of patients. Reduced cytosis, percentage and absolute content of neutrophils, and absolute content of lymphocytes and eosinophils in induced sputum were observed with CB patients in the combined therapy group. A reduced content of lymphocytes and an increase in macrophages were observed with CB patients in the monotherapy group. A significant decline in tumour necrosis factor (TNF)-α content in sputum was observed with both therapeutic regimens, although a statistically significant decline in serum TNFα (10.85 ng/L to 5.58 ng/L; p = 0.03) and reduced interleukin-8 in sputum (311.94 ng/L to 122.02 ng/L; p = 0.027) were observed with patients given combined therapy.

Conclusion: The study showed greater efficacy of long-term treatment with fenspiride and ipratropium bromide compared with ipratropium bromide alone in patients with CB. This combination regimen can be recommended for the reduction of inflammation and prevention of disease progression in patients with CB and may also be useful in patients with COB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Table I
Table II
Table III

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Bezlepko AV. Experience of long-term application of fenspiride (Eurespal) for treatment of patients with chronic obstructive bronchitis. Pulmonology 2002; 3: 76–82

    Google Scholar 

  2. Edvard Y, Kato G, Bodinier MC, et al. Fenspiride et inflammation en pharmacologie expérimentale. Eur Respir Rev 1991; 1(2): 33–40

    Google Scholar 

  3. Pipy B, Pinelli E, Forgue MF, et al. Fenspiride inhibits arachidonic acid metabolite production and cytolic Ca2+ increase by inflammatory macrophages [letter]. Eur Respir J 1992; 5: 237

    Google Scholar 

  4. Carre PH, Pipy B, Pinelli E, et al. In vitro effects of fenspiride on the production of free oxygen radicals, prostaglandins and leukotrienes by guinea-pig alveolar macrophages. Eur Respir Rev 1991; 1(2): 79–85

    Google Scholar 

  5. Volkova LI, Bukreeva EB, Boyarko VV, et al. Experience of fenspiride (Eurespal) application upon chronic bronchitis exacerbation. Clin Pharmacol Ther 2000; 5(9): 65–8

    Google Scholar 

  6. Kunitsyna YL, Shmelev EI. Anti-inflammatory therapy of patients with chronic obstructive pulmonary disease. Pulmonology 2003; 2: 111–6

    Google Scholar 

  7. Ovcharenko SI. Anti-inflammatory therapy of chronic bronchitis. RMJ 2001; 9(5): 20–4

    Google Scholar 

  8. Akoun G, Arnaud F, Blanchon F, et al. Effect du fenspiride sur la fonction respiratoire et gazométrie de patients présentant une bronchopathie chronique obstructive stable. Eur Respir Rev 1991; 1: 51–6

    Google Scholar 

  9. Oliveri D, Del Donno M. Etude de faction du fenspiridi (pneumorel 80 mg) sur la clairance mucociliare chez le, bronchitique chronique. J Intern Med 1987; 96: 395–8

    Google Scholar 

  10. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report 2001; 3 (1)

  11. Fahy JV, Liu J, Wong H, et al. Cellular and biochemical analysis of induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am Rev Respir Dis 1993; 147: 1126–31

    PubMed  CAS  Google Scholar 

  12. Lensmar C, Elmberger G, Sandgren P, et al. Leukocyte counts and macrophage phenotypes in induced sputum and bronchoalveolar lavage fluid from normal subjects. Eur Respir J 1998; 12: 595–600

    Article  PubMed  CAS  Google Scholar 

  13. Rutgers SR, Timens W, Kaufman HF. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15: 109–15

    Article  PubMed  CAS  Google Scholar 

  14. Konmlev AD, Kalinina NM, Sysoev KA, et al. Cytokine profile of patients with chronic obstructive pulmonary disease. Med Immunol 2002; 4(1): 87–92

    Google Scholar 

  15. Bhowmik A, Seemungal T, Sapsford RJ, et al. Cytokines in induced sputum during exacerbations of chronic obstructive pulmonary disease. Thorax 2000; 55: 114–20

    Article  PubMed  CAS  Google Scholar 

  16. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530–4

    PubMed  CAS  Google Scholar 

  17. Richman-Eisenstadt JB, Jorens PG, Hebert CA, et al. Interleukine-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 1993; 264: L413–8

    Google Scholar 

  18. Ketlinsky SA, Kalinina NM. Cytokines of mononuclear phagocytes in regulation of inflammation and immunity [letter]. Immunology 1995; 3: 15

    Google Scholar 

  19. Chereshnev VA, Gusev EY. Inflammation immunology: role of cytokines. Med Immunol 2001; 3(3): 361–8

    Google Scholar 

  20. Linden M, Rasmussen JB, Pitulainen E, et al. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis 1993; 148: 1226–32

    PubMed  CAS  Google Scholar 

  21. Culpitt SV, de Matos C, Russell RE, et al. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1371–6

    Article  PubMed  Google Scholar 

  22. Stockleu RA, Bauley DL. Validation of assays for inflammatory mediators in sputum. Eur Respir J 2000; 15: 779–81

    Google Scholar 

  23. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112: 505–10

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Publication assistance was provided by Servier Russia.

The authors have no potential conflicts of interest that are directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

  1. Siberian Medical University, Tomsk, Russia

    L. I. Volkova, A. A. Budkova, N. N. Filonova, E. I. Khristolyubova, E. B. Kutuzova, N. V. Koroleva, T. T. Radzivil & Z. R. Aminova

  2. Pulmonology Research Institute, Russian Federation Ministry of Health, Moscow, Russia

    A. G. Chuchalin

Authors
  1. L. I. Volkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. A. Budkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. N. Filonova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. I. Khristolyubova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. B. Kutuzova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. V. Koroleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. T. Radzivil
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Z. R. Aminova
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. G. Chuchalin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volkova, L.I., Budkova, A.A., Filonova, N.N. et al. Efficacy of Supplemental Anti-Inflammatory Therapy with Fenspiride in Chronic Obstructive and Nonobstructive Bronchitis. Clin. Drug Investig. 25, 257–264 (2005). https://doi.org/10.2165/00044011-200525040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200525040-00005

Keywords

Search

Navigation